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benzodiazepine withdrawal syndromeuse during the perioperative period and an elevated incidence of delirium. However, no study has focused on the
time course of BZDRA use, including continuation, discontinuation, initiation, and no use. This study aimed to ex-
amine the influence of the time course of BZDRA use on post-operative delirium.Background: Several studies have investigated the association betweenbenzodiazepine receptor agonist (BZDRA)
Methods: This retrospective cohort study was conducted by reviewing medical records. We included patients
who were scheduled for surgery under general anesthesia and had been referred to a liaison psychiatrist for
pre-operative psychiatric assessment. The patients were classified into four groups based on the pre- and post-
operative time course of oral BZDRA use, as follows: continuation, discontinuation, initiation, and no use
(never used). The primary outcomewas the prevalence of post-operative delirium in non-intensive care unit set-
tings.We also performed stratified analyses according to age, the presence of cognitive impairment, the presence
of delirium history, and antipsychotic drug use on admission.
Results: Among 250 patients, 78 (31%) developed post-operative delirium. The Discontinuation group had a
higher rate of delirium (49%, 24/49) than the other groups (Continuation [14%, 4/29]; Initiation [38%, 3/8],
Never used [29%, 47/164], p = 0.008).
Conclusions: Abrupt discontinuation of BZDRAs during the perioperative period may be a risk factor for post-
operative delirium and should therefore be avoided.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Delirium is the most prevalent mental disorder among hospitalized
patients. In medical wards, the prevalence of delirium among hospital-
ized patients ranges from 10% to 30% [1]; moreover, 51% of patients de-
velop post-operative delirium [1]. Post-operative delirium is associated
with higher rates of cognitive/functional decline, severe acute illness,
prolonged length of hospitalization, and economic costs [2–5]. Old age
(over 70 years), cognitive impairment, and a history of delirium are
the primary risk factors for delirium [6–9]; further, perioperative usey, Graduate School of Medical
jii-cho, Kawaramachi-Hirokoji,
nc. This is an open access article undof benzodiazepine receptor agonists (BZDRAs) has also been reported
as a risk factor [6,10].
BZDRAs are widely used among patients with insomnia and anxiety
[11–13], and are generally considered to be safe and effective during
short-term use. However, extended use (for >2 months) may cause in-
creased drug tolerance, dependence, and other adverse effects such as
falls and cognitive disturbances [14,15]. Long-term users are advised
to discontinue BZDRAs to avoid adverse effects [16–20]; however,
abrupt discontinuation frequently leads to benzodiazepine withdrawal
syndrome, which can lead to severe symptoms, including agitation, sei-
zures, and delirium. A previous study among hospitalized patients re-
ported that delirium was related to benzodiazepine withdrawal in
approximately 20% (4/19) of patients aged 65 years and older [21].
While there have been many reports describing the association be-
tween BZDRA use and post-operative delirium [6,10,22–26], no cohort
study has compared the risk of post-operative delirium after continued,er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with that in patients not using BZDRAs at all. This study aimed to deter-
mine the influence of continuation, discontinuation, and initiation of
oral BZDRA administration on post-operative delirium among hospital-
ized patients in the non-intensive care unit (ICU) setting.
2. Material and methods
2.1. Study design and patient population
This retrospective cohort study was conducted at the University
Hospital of Kyoto Prefectural University of Medicine (KPUM), which is
a 1065-bed tertiary care center in Kyoto prefecture, Japan.
Perioperative patients admitted between January 2016 and Decem-
ber 2018 who had received preventive intervention from a liaison psy-
chiatrist before surgery were included in our study. Attending surgeons
decided whether the consultation-liaison service (CLS) should be
sought for preventive intervention. There were no specific criteria for
these requests; however, surgeons often requested the interventions
to prevent delirium in patients at risk, such as thosewith older age, cog-
nitive impairment, and a history of delirium or severe surgical invasion.
In caseswhere surgeons requested the CLS, theymade the final decision
on whether medications should be adjusted based on advice and guid-
ance from the latter.
Weconsidered thateach admissionevent during the studyperiod in-
volved one individual patient, regardless of readmission, because re-
peated requests for preventive intervention are rare in cases where the
same patient undergoes repeated operations in a short period of time.
We excluded patients undergoing local anesthesia for surgery to en-
sure a similar degree of surgical invasion among the study group. In ad-
dition, we also excluded patients who died within 24 h of surgery, had
an ICU stay beyond the study period, and received intervention for
assessing organ transplant eligibility. The Institutional Review Board of
KPUM approved the study and waived the requirement for informed
consent because all data were obtained as part of daily routine practice.
2.2. Consultation-liaison interventions
The CLS of theDepartment of Psychiatry at the KPUMprovides inter-
ventions in the form of guidance regarding the treatment and preven-
tion of mental disorders for patients in the general medical ward.
For patients with significant risk factors for delirium (e.g., older age,
history of delirium, cognitive impairment, and alcohol use disorders), li-
aison psychiatrists advise reduction or discontinuation of BZDRAs and
anticholinergic drugs; they advise the prescription of other hypnotic
drugs such as ramelteon, suvorexant, or trazodone, the last of which is
frequently prescribed for hospitalized patients with insomnia in Japan
owing to its efficacy in managing the symptoms of delirium [27].
2.3. BZDRA and the time course of BZDRA use
All benzodiazepines and non-benzodiazepines, including hypnotic,
anti-anxiety, and antiepileptic drugs, were considered as BZDRAs. The
following BZDRAs were available for use at the study site and selected
for our study: alprazolam, bromazepam, brotizolam, clonazepam,
clotiazepam, cloxazolam, diazepam, estazolam, eszopiclone, etizolam,
ethyl loflazepate,flunitrazepam, lorazepam, lormetazepam, nitrazepam,
quazepam, triazolam,zolpidem,andzopiclone.Weinvestigatedwhether
the participants received BZDRAs during the perioperative period.
The participants were classified into the following four groups based
on the time course of BZDRA use: “Continued,” “Discontinued,” “Initi-
ated,” and “Never used.” The “Continued” group had been taking
BZDRAs continuously from admission to the end of the study period.
Participants who resumed BZDRAs within 2 days after surgery were
considered to be in the “Continued” group if medications were
interrupted due to post-operative fasting; this was based on the fact2
that withdrawal symptoms usually occur within 48 h of short-acting
BZDRA administration [28]. The “Discontinued” group included partici-
pants who were taking BZDRAs on admission but discontinued them
after surgery; those who resumed treatment at more than 3 days after
surgery were also included in this group. Since patients are usually ad-
mitted to the hospital a few days before surgery, BZDRAs were
discontinued abruptly. Participants whowere not taking BZDRAs on ad-
mission but received new BZDRA prescriptions (including rescue use)
post-operatively were classified in the “Initiated” group. Finally, those
whodid not take BZDRAs at any time during the study periodwere clas-
sified into the “Never-used” group.2.4. Data collection and outcomes
Data on baseline patient characteristics, including background infor-
mation, length of hospitalization, operative times, Charlson comorbidity
index [29], psychiatric comorbidities such as cognitive impairment and
alcohol use disorders, delirium history, and perioperative use of psychi-
atric medications, including oral BZDRAs and antipsychotics, were ob-
tained from electronic medical records. Psychiatric comorbidities were
diagnosed according to the Diagnostic and Statistical Manual of Mental
Disorders, fifth edition (DSM-5) criteria based on the information col-
lected from the medical records [30].
BZDRAs were classified into two categories based on the duration of
action, namely, ultrashort−/short-term and intermediate/long-term
BZDRAs. Ultrashort- (including eszopiclone, triazolam, zolpidem, and
zopiclone), short- (including brotizolam, clotiazepam, etizolam, and
lormetazepam), intermediate- (including alprazolam, bromazepam, es-
tazolam, lorazepam, and nitrazepam), and long- (including clonaze-
pam, diazepam, ethyl loflazepate, flunitrazepam, and quazepam)
acting BZDRAs have a half-life of <6, 6–12, 12–24, and > 24 h, respec-
tively [31,32].
The primary outcomewas the prevalence of post-operative delirium
in the non-ICU setting. We reviewed the medical records till
post-operative day 14 to determine the occurrence of delirium. Delir-
ium (including hyperactive, hypoactive, and mixed types of delirium)
that occurred up to 7 days after surgery was defined as post-operative
delirium, based on a previous report [33]. In addition, any delirium
that developed within 7 days of ICU discharge (and within 14 days
after surgery) was also considered to be post-operative delirium. We
also examined delirium occurring in the ICU; however, we did not eval-
uate this in the current study, as we intended to investigate the associ-
ation between oral BZDRA use and the development of post-operative
delirium in a general ward setting.
Deliriumwas diagnosed according to DSM-5, based on the available
information collected from the medical records. The four reviewers, in-
cluding three experienced psychiatrists who were familiar with the
clinical practice of delirium diagnosis, checked all relevant information
and confirmed the diagnosis of delirium through a consensus.2.5. Statistical analysis
Continuous variables, presented as means and standard deviations
or medians and interquartile ranges (IQRs), were compared using t- or
Wilcoxon rank-sum tests. Categorical variables, presented as counts
and percentages, were compared using chi-square or Fisher's exact
tests. The prevalence of delirium was calculated as the number of pa-
tients with delirium divided by the number of patients in each group.
We performed stratified analysis to adjust for certain confounding fac-
tors associated with the development of delirium (age 70 years or
higher, presence of cognitive impairment, history of delirium, and anti-
psychotic drug use on admission) as multivariate analysis could not be
used to compare the prevalence in the four groups after examination
with chi-square tests.
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tistically significant. All statistical analyses were conducted using the
JMP 14.0 for Mac software package (SAS Institute Inc).
3. Results
3.1. Baseline characteristics
We included 250 patients in the final analysis (Fig. 1); they had a
mean age of 67 years and 143 (57.2%) were male (Table 1). Among
them, 51 (20.4%) and 32 (12.8%) experienced cognitive impairment
and had a history of delirium, respectively. According to the time course
of BZDRA use, 29 (11.6%), 49 (19.6%), 8 (3.2%), and 164 (65.6%) patients
were classified into “Continued,” “Discontinued,” “Initiated,” and
“Never-used” groups, respectively. The cardiovascular surgery depart-
ment had the highest number of patients referred for liaison preventive
intervention (n = 70, 28.0%) (Table 1).
Inter-group comparison showed that the “Continued” group had the
shortest operative duration (198 min, IQR: 79, 269.5) and the highest
rate of psychiatric comorbidities (76%, 22/29) and antipsychotic drug
usage on admission (24.1%, 7/29). The “Discontinued” group had the
highest mean age (73.1 years, SD = 9.6). Only three patients in this
group were not under treatment with other sleep medications
(ramelteon, suvorexant, or trazodone), and only one patient was not
under treatment with any psychotropic medication at all. In contrast,
the mean age of the “Initiated” group was the lowest (53.5 years,
SD = 23.9), and none of the patients were taking antipsychotics. The
“Never-used” group had the highest rate of cognitive impairment
(25.0%, 41/164).
3.2. Outcomes
The prevalence of post-operative delirium in all patients was 31.2%
(78/250) (Table 2). The “Discontinued” group had the highest rate
among the four groups (49.0%, 24/49), and “Continued” group had the
lowest (13.8%, 4/29). There was a significant difference in the preva-
lence of delirium among the four groups (p = 0.008) (Table 2).
On stratified analysis, we observed that the prevalence of post-
operative delirium was the highest in the “Discontinued” group and in
patients who did not have cognitive impairment, a history of delirium,
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BZDRA use on admission
Continued (n=29) Discontinued(n=49)
Fig. 1. Flowchart of the patients who met the inclusion criteria
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considered strong risk factors for the development of post-operative de-
lirium. Even after excluding patients aged 70 years and older, whowere
at high risk for delirium, the “Discontinued” group continued to show
the highest prevalence; however, there was no significant difference
in the rates between the groups (Table 3).
The prevalence of delirium among patients in the “Continued” and
“Discontinued” groups taking short-acting drugs was 50% and 51%, re-
spectively. The incidence of delirium among patients taking long-
acting drugs was 4% and 38%, respectively. In addition, the prevalence
of post-operative delirium in the “Discontinued” group according to
the type of BZDRA used on admission was 51% and 38% for ultrashort/
short and intermediate/long-acting BZDRAs, respectively (p = 0.70).
Conversely, in the “Continued” group, the prevalence was 50% and 4%
respectively, with a significantly higher rate in the group taking
ultrashort/short-acting BZDRAs (p = 0.02).
4. Discussion
In this study, we assessed the relationship between the time course
of oral BZDRAuse (continuation, discontinuation, initiation, and no use)
and the occurrence of post-operative delirium in general ward inpa-
tients; an independent association was observed between the discon-
tinuation of BZDRA use and post-operative delirium. Many previous
studies have reported an association between delirium and BZDRA ad-
ministration; however, a majority of these studies analyzed ICU pa-
tients, who received intravenous BZDRA for sedation and anxiety
reduction [22–25].
In contrast, there have been few studies on the association between
oral psychoactive medications and post-operative delirium in general
ward patients. A nested case-control study by Marcantonio et al. on a
prospective cohort of post-operative patients with delirium reported
an association between oral BZDRA and meperidine use and delirium
occurrence (odds ratio, 3.0; 95% confidence interval, 1.3–6.8) [10]. Sim-
ilarly, a cohort study by Gaudreau et al. among hospitalized patients
with cancer reported that the use of oral BZDRAs, corticosteroids, and
opioidswas an independent risk factor for delirium [26]. These previous
findings indicate an association between the use of some drugs during
hospitalization, including BZDRAs, and the development of delirium.
To our knowledge, the present study is the first to demonstrate an asso-
ciation between the time course of BZDRA use (continuation, discontin-






hours after surgery  (n=1)
or more than 2 weeks (n=11)
Non-BZDRA use on admission
Initiated (n=8) Never-used (n=164)
for the study. BZDRA: benzodiazepine receptor agonists.
Table 1
Demographics and clinical variables on admission.
Variables Total Continued Discontinued Initiated Never used p-value
N = 250 N = 29 N = 49 N = 8 N = 164
Age, mean (SD) 66.7 (17.1) 57.9 (16.9) 73.1 (9.6) 53.5 (23.9) 67.0 (17.7) <0.001
Male sex, n (%) 143 (57.2) 9 (31.0) 29 (59.2) 5 (62.5) 100 (60.9) 0.03
Length of stay, median (IQR) 30 (15, 45) 13 (7, 24) 34 (17, 51) 28 (15, 46) 33 (18, 46) 0.006
Operative time, median (IQR) 291(141, 443) 162 (79,270) 326 (185, 527) 232 (91, 303) 314 (159, 477) 0.007
Charlson comorbidity index ≧ 3, n (%) 43 (17.2) 3 (10.3) 10 (20.4) 0 (0) 30 (18.3) 0.37
History of delirium 32 (12.8) 3 (10.3) 6 (12.2) 1 (12.5) 22 (13.4) 0.97
Psychiatric comorbidity
All psychiatric comorbidities, n (%) 101 (40.4) 22 (75.9) 15 (30.6) 4 (50.0) 60 (36.6) <0.001
Psychotic disorder, n (%) 8 (3.2) 5 (17.2) 1 (2.0) 0 (0) 2 (1.2) <0.001
Mood disorder, n (%) 16 (6.4) 12 (41.4) 1 (2.0) 1 (12.5) 2 (1.2) <0.001
Mental retardation, n (%) 14 (5.6) 2 (6.9) 0 (0) 0 (0) 12 (7.3) 0.22
Cognitive impairment, n (%) 51 (20.4) 0 (0) 9 (18.4) 1 (12.5) 41 (25.0) 0.019
Alcohol use disorder, n (%) 11 (4.4) 0 (0) 6 (12.2) 1 (12.5) 4 (2.4) 0.010
Medication on admission
Antipsychotic drugs, n (%) 21 (8.4) 7 (24.1) 3 (6.1) 0 (0) 11 (6.7) 0.012
Ultrashort/short-acting BZDRAs, n (%) 47 (60.3) 6 (20.7) 41 (83.6) NA NA <0.001
Main treatment department
Cardiovascular surgery, n (%) 70 (28.0) 5 (17.2) 14 (28.6) 1 (12.5) 50 (30.5) 0.37
Otolaryngology, n (%) 41 (16.4) 4 (13.8) 9 (18.4) 1 (12.5) 27 (16.5) 0.95
Gastroenterology, n (%) 38 (15.2) 1 (3.5) 10 (20.4) 0 (0) 27 (16.5) 0.12
SD, Standard deviation; IQR, Interquartile range; NA, Not applicable
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BZDRA use were considered to be related to the patient characteristics
in each group. The prevalence in the “Continued” group (13.8%) was
lower than that in the “Never-used” group (28.7%). The “Continued”
group had a high proportion of patients with psychiatric comorbidities.
BZDRAsmay have been continued for the stabilization of psychiatric co-
morbidities rather than to mitigate the risk of developing delirium;
therefore, this group had the highest number of prescriptions for anti-
psychotics on admission, and all patients remained on antipsychotics
during the study period. In the “Initiated” group, BZDRAs were initiated
post-operatively because of the difficulty in controlling insomnia; how-
ever, the prevalence of delirium in the “Initiated” group (37.5%) was
higher than that in the “Never-used” group, where the patients had
the second highest mean age and the highest proportion of cognitive
impairment. Cognitive impairment was considered to be a risk factor
for delirium; this may have been related to the lack of BZDRA adminis-
tration in the “Never-used” group.
The “Discontinued” grouphad thehighestmean age,whichwas con-
sidered a risk factor for delirium, and led psychiatrists to recommend
BZDRA reduction or discontinuation. Liaison psychiatrists recom-
mended that BZDRAs should be discontinued for the purpose of reduc-
ing the risk of delirium, especially in elderly patients, and those with a
history of delirium and cognitive impairment. The attending surgeon,
therefore, often discontinued BZDRAs. In this study, all participants in
the “Discontinued” group had abruptly discontinued BZDRAs; they
were admitted to the hospital a few days before surgery and the CLS
was requested even later; hence, discontinuation following the advice
of the CLS had to be abrupt.
Unlike gradual tapering, abrupt BZDRA discontinuation is likely to
cause withdrawal syndromes, including insomnia and delirium [31].
Abrupt discontinuation of BZDRAs after surgery could induce reboundTable 2
Prevalence of delirium.
Total Continued
N = 250 N = 29
Post-operative delirium, n (%) 78 (31.2) 4 (13.8)
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insomnia and withdrawal delirium in patients who had been taking
BZDRAs for a long time. Because we did not collect data regarding the
duration of BZDRA intake before surgery, inferences regarding the im-
pact of duration of BZDRA administration on discontinuation-
associated delirium cannot be drawn. However, it is estimated that
the number of patients who develop post-operative delirium due to
BZDRA discontinuation is not small, as BZDRAs are routinely prescribed
to many patients in Japan.
In order to adjust for potential confounding factors, stratified analy-
sis was conducted according to the absence of cognitive impairment,
history of delirium, and antipsychotic drug usage. Stratified analysis re-
vealed that the “Discontinued” group had the highest rate of delirium
occurrence. This indicates that post-operative abrupt BZDRA discontin-
uation affects delirium even after adjustment for previously reported
risk factors of delirium (cognitive impairment and delirium history)
[34]. Similar findings were also obtained in the absence of antipsychotic
use, which reportedly reduces the onset of delirium [35,36].
In addition, the prevalence of delirium in patients in the “Continued”
groupwhoused ultrashort/short-acting BZDRAs (50%)was significantly
higher than that in those who used intermediate/long-acting BZDRAs
(4%); however, there was no significant difference in the prevalence of
delirium between those using ultrashort/short- and intermediate/
long-acting BZDRAs in the “Discontinued” group. As patients generally
undergo surgery soon after admission, it may be difficult to change
the type of BZDRA after admission. However, these results suggest
that it may be advisable to switch from ultrashort/short-acting BZDRAs
to intermediate/long-acting types if they are continued after surgery.
This study has some strengths and limitations. First, as this was a
four-group analysis of the time course of BZDRA use, it was not possible
to perform multivariate analysis, and only simple adjustment for con-
founding factorswas performed through stratification. In order to assessDiscontinued Initiated Never used p-value
N = 49 N = 8 N = 164
24 (49.0) 2 (11.8) 47 (28.7) 0.008
Table 3
Stratified analysis.
Continued Discontinued Initiated Never used p-value
Patients without cognitive impairment, n 29 40 7 123
Post-operative delirium, n (%) 4 (13.8) 19 (47.5) 2 (28.6) 32 (26.0) 0.016
Patients without a history of delirium, n 26 43 7 142
Post-operative delirium, n (%) 3 (11.5) 21 (48.8) 3 (42.9) 36 (25.3) 0.003
Patients with no antipsychotic use on admission, n 22 46 8 153
Post-operative delirium, n (%) 4 (18.2) 24 (52.2) 3 (37.5) 44 (28.8) 0.011
Patients under 70 years of age, n 20 15 6 68
Post-operative delirium, n (%) 1 (5.0) 5 (33.3) 1 (16.7) 10 (14.7) 0.15
⁎Prescribed at the time of admission
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operative delirium, it is preferable to focus only on the “Continued”
and “Discontinued” groups and performmultivariate analysis. However,
this study intended to investigate the clinical use of BZDRAs before and
after surgery and compare the prevalence of delirium in the “Contin-
ued,” “Discontinued,” “Initiated,” and “Never-used” groups. The notion
that BZDRA has a negative effect on post-operative delirium is popular
in consultation-liaison psychiatry; we intended to identify patients
who discontinued, continued, or initiated the use of BZDRAs and com-
pare the prevalence of post-operative delirium among patients who
used and did not use these drugs under similar circumstances.
Second, although the presence or absence of BZDRA medication
upon admission was considered, the actual BZDRA administration his-
tory was not determined. An individual survey is required during ad-
mission to accurately determine administration history. Finally, this
study collected data through a retrospective review of medical records;
therefore, wemay have underestimated the occurrence of delirium due
to cases being overlooked. Notably, a previous report has indicated that
hypoactive delirium is likely to being missed [37]. However, since this
was a retrospective cohort study, daily clinical practice information
could be observed and analyzed without involving the medical staff.
The design also allowed a comprehensive analysis of continuation, dis-
continuation, and initiation of BZDRA use as a risk factor for delirium.
5. Conclusions
These findings indicate a relatively high occurrence of delirium in
patients in the “Discontinued” group, which could be attributed to the
withdrawal syndrome or insomnia resulting from BZDRA discontinua-
tion. In BZDRA users, it is important to consider BZDRA use carefully
during the perioperative period. Moreover, gradual tapering is impor-
tant in outpatient settings for patients who continue BZDRA use. Al-
though BZDRA use is a known risk factor, abrupt discontinuation
should be avoided to reduce the risk of delirium.
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